Clinical Trial Update: Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ferric carboxymaltose for improving exercise capacity in kidney transplant recipients with iron deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Iron-deficiency, Transplant-Related Disorder | Phase 3 | Status: COMPLETED